Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer
Grant D Stewart, Fiach C O'Mahony, Alexander Laird, Sukaina Rashid, Sarah A Martin, Lel Eory, Alexander L R Lubbock, Jyoti Nanda, Marie O'Donnell, Alan Mackay, Peter Mullen, S Alan McNeill, Antony C P Riddick, Michael Aitchison, Daniel Berney, Axel Bex, Ian M Overton, David J Harrison, Thomas Powles, Grant D Stewart, Fiach C O'Mahony, Alexander Laird, Sukaina Rashid, Sarah A Martin, Lel Eory, Alexander L R Lubbock, Jyoti Nanda, Marie O'Donnell, Alan Mackay, Peter Mullen, S Alan McNeill, Antony C P Riddick, Michael Aitchison, Daniel Berney, Axel Bex, Ian M Overton, David J Harrison, Thomas Powles
Abstract
Background: There is a lack of biomarkers to predict outcome with targeted therapy in metastatic clear cell renal cancer (mccRCC). This may be because dynamic molecular changes occur with therapy.
Objective: To explore if dynamic, targeted-therapy-driven molecular changes correlate with mccRCC outcome.
Design, setting, and participants: Multiple frozen samples from primary tumours were taken from sunitinib-naïve (n=22) and sunitinib-treated mccRCC patients (n=23) for protein analysis. A cohort (n=86) of paired, untreated and sunitinib/pazopanib-treated mccRCC samples was used for validation. Array comparative genomic hybridisation (CGH) analysis and RNA interference (RNAi) was used to support the findings.
Intervention: Three cycles of sunitinib 50mg (4 wk on, 2 wk off).
Outcome measurements and statistical analysis: Reverse phase protein arrays (training set) and immunofluorescence automated quantitative analysis (validation set) assessed protein expression.
Results and limitations: Differential expression between sunitinib-naïve and treated samples was seen in 30 of 55 proteins (p<0.05 for each). The proteins B-cell CLL/lymphoma 2 (BCL2), mutL homolog 1 (MLH1), carbonic anhydrase 9 (CA9), and mechanistic target of rapamycin (mTOR) (serine/threonine kinase) had both increased intratumoural variance and significant differential expression with therapy. The validation cohort confirmed increased CA9 expression with therapy. Multivariate analysis showed high CA9 expression after treatment was associated with longer survival (hazard ratio: 0.48; 95% confidence interval, 0.26-0.87; p=0.02). Array CGH profiles revealed sunitinib was associated with significant CA9 region loss. RNAi CA9 silencing in two cell lines inhibited the antiproliferative effects of sunitinib. Shortcomings of the study include selection of a specific protein for analysis, and the specific time points at which the treated tissue was analysed.
Conclusions: CA9 levels increase with targeted therapy in mccRCC. Lower CA9 levels are associated with a poor prognosis and possible resistance, as indicated by the validation cohort.
Patient summary: Drug treatment of advanced kidney cancer alters molecular markers of treatment resistance. Measuring carbonic anhydrase 9 levels may be helpful in determining which patients benefit from therapy.
Trial registration: ClinicalTrials.gov NCT01024205.
Keywords: Biomarker; CA9; Renal cancer; VEGF TKI.
Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Figures
References
- Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–3590.
- Stewart G.D., O’Mahony F.C., Powles T., Riddick A.C.P., Harrison D.J., Faratian D. What can molecular pathology contribute to the management of renal cell carcinoma? Nat Rev Urol. 2011;8:255–265.
- Tran H.T., Liu Y., Zurita A.J., et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012;13:827–837.
- Druker B.J., Guilhot F., O’Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417.
- Slamon D., Eiermann W., Robert N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–1283.
- Powles T., Hutson T.E. Difficulty in predicting survival in metastatic renal cancer. Lancet Oncol. 2012;13:859–860.
- Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–892.
- Sharpe K., Stewart G.D., Mackay A., et al. The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin Cancer Res. 2013;19:6924–6934.
- O’Mahony F.C., Nanda J., Laird A., et al. The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers. J Vis Exp. 2013:e50221.
- Faratian D., Um I., Wilson D.S., Mullen P., Langdon S.P., Harrison D.J. Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy. Eur J Cancer. 2011;47:1420–1431.
- Johnson W.E., Li C., Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostat Oxf Engl. 2007;8:118–127.
- Neeley E.S., Kornblau S.M., Coombes K.R., Baggerly K.A. Variable slope normalization of reverse phase protein arrays. Bioinformatics. 2009;25:1384–1389.
- Camp R.L., Chung G.G., Rimm D.L. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8:1323–1327.
- O’Mahony F.C., Faratian D., Varley J., et al. The use of automated quantitative analysis to evaluate epithelial-to-mesenchymal transition associated proteins in clear cell renal cell carcinoma. PLoS ONE. 2012;7:e31557.
- Camp R.L., Dolled-Filhart M., Rimm D.L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–7259.
- Gerth-Kahlert C., Williamson K., Ansari M., et al. Clinical and mutation analysis of 51 probands with anophthalmia and/or severe microphthalmia from a single center. Mol Genet Genomic Med. 2013;1:15–31.
- Natrajan R., Weigelt B., Mackay A., et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat. 2010;121:575–589.
- Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57:289–300.
- Wykoff C.C., Beasley N.J., Watson P.H., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60:7075–7083.
- Luong-Player A., Liu H., Wang H.L., Lin F. Immunohistochemical reevaluation of carbonic anhydrase IX (CA IX) expression in tumors and normal tissues. Am J Clin Pathol. 2014;141:219–225.
- Bui M.H.T., Seligson D., Han K., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802–811.
- Zhang B.Y., Thompson R.H., Lohse C.M., et al. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up. BJU Int. 2013;111:1046–1053.
- Clement J.M., McDermott D.F. The high-dose aldesleukin (IL-2) “select” trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2009;7:E7–E9.
- Choueiri T.K., Cheng S., Qu A.Q., Pastorek J., Atkins M.B., Signoretti S. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET) Urol Oncol. 2013;31:1788–1793.
- Garcia-Donas J., Leandro-García L.J., González Del Alba A., et al. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol. 2013;24:2409–2414.
- Parkkila S., Rajaniemi H., Parkkila A.K., et al. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci U S A. 2000;97:2220–2224.
- Závada J., Závadová Z., Pastorek J., Biesová Z., Jezek J., Velek J. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer. 2000;82:1808–1813.
- Huang D., Ding Y., Li Y., et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 2010;70:1053–1062.
Source: PubMed